Immunovant to Report Financial Results for Quarter Ended June 30, 2021
Immunovant, Inc. (Nasdaq: IMVT) will host a conference call and audio webcast on August 9, 2021, at 8 a.m. ET, to discuss its financial results for the first fiscal quarter ended June 30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) will host a conference call and audio webcast on August 9, 2021, at 8 a.m. ET, to discuss its financial results for the first fiscal quarter ended June 30, 2021. Following prepared remarks, there will be a live Q&A session for investors. Immunovant is focused on developing IMVT-1401, a fully human anti-FcRn monoclonal antibody aimed at treating autoimmune diseases associated with pathogenic IgG antibodies.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +0.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will host a conference call and audio webcast on Monday, August 9, 2021 at 8 a.m. ET to discuss financial results for its fiscal first quarter ended June 30, 2021.
Following prepared remarks, the call will include a live question-and-answer session for the investment community. To access the webcast, please visit Immunovant’s website at www.immunovant.com.
Participants may also dial in using the numbers provided below:
Toll Free: 1-877-407-9039
Toll/International: 1-201-689-8470
An archived webcast recording will be available on Immunovant’s website for a limited time.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
Tom Dorney
Investor Relations
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.